Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...

Anavex Life Sciences (NASDAQ:AVXL) outlined its strategy to develop oral, precision-medicine therapies for central nervous ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

If you are wondering whether Praxis Precision Medicines at around US$280.83 is still offering value after its recent run, ...

Mirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for ...

MTAR may no longer be hidden for some, but its real test is durability. Operating quietly across India’s most demanding ...

Prof. Ciro Leonardo Pierri's expertise in structural biology, mitochondrial carrier modeling, and drug targeting—demonstrated ...

Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its ...

Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (nelivaptan) in 338 patients with Major Depressive Disorder (MDD), using a ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. /CNW/ — Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth ...

Enhanced Genomics ('Enhanced' or 'the Company'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for co ...